Relay Therapeutics Inc
NASDAQ:RLAY

Watchlist Manager
Relay Therapeutics Inc Logo
Relay Therapeutics Inc
NASDAQ:RLAY
Watchlist
Price: 4.34 USD -9.21% Market Closed
Market Cap: 726.4m USD

Net Margin
Relay Therapeutics Inc

-1 698%
Current
-11 473%
Average
-7.9%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 698%
=
Net Income
-603.7m
/
Revenue
35.6m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Relay Therapeutics Inc
NASDAQ:RLAY
729.1m USD
-1 698%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
308.6B USD
9%
US
Amgen Inc
NASDAQ:AMGN
142.6B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
113B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.7B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.1B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
76.7B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
38.8B EUR
-5%

Relay Therapeutics Inc
Glance View

Market Cap
724.3m USD
Industry
Biotechnology

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 245 full-time employees. The company went IPO on 2020-07-16. The firm is focused on transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The firm is advancing a pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008, RLY-2608 and RLY-1971. Its RLY-1971 binds and stabilizes Src homology region two (SH2)-containing protein tyrosine phosphatase two (SHP2) in its inactive conformation. Its RLY-4008, is it inhibitor of fibroblast growth factor receptor 2 (FGFR2), enriched for patients with advanced solid tumors having oncogenic FGFR2. The firm uses its Dynamo platform to focus on precision oncology. The company is also advancing several early programs focused on other precision oncology and genetic disease targets.

RLAY Intrinsic Value
1.91 USD
Overvaluation 56%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 698%
=
Net Income
-603.7m
/
Revenue
35.6m
What is the Net Margin of Relay Therapeutics Inc?

Based on Relay Therapeutics Inc's most recent financial statements, the company has Net Margin of -1 698%.

Back to Top